Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COUNTERMAND

Financiado

Cerrado

Small molecule inhibitors of bacterial communication a new strategy for tackli...

Small molecule inhibitors of bacterial communication a new strategy for tackling antimicrobial resistance Bacteria which are resistant to antibiotics currently result in 33,000 deaths per annum in Europe alone. Antimicrobial Resistance (AMR) will potentially cost the EU an estimated €1.5 billion annually in healthcare expenses and pro... ver más

29/04/2025

UCC

197K€

Presupuesto del proyecto: 197K€

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-30

MSCA-IF-2020: Individual Fellowships Objective:The goal of the Individual Fellowships is to enhance the creative and innovative potential...

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UCC

196.59K€ | Lider

Proyectos interesantes

COMBACTE-NET

Medical Technol...

Data Science

221M€ Cerrado

COMBACTE-NET

Medical Technol...

Data Science

221M€ Cerrado

RARE

Medical Technol...

Data Science

100K€ Cerrado

PID2019-108643GA-I00

Medical Technol...

Data Science

85K€ Cerrado

ABOLED

Medical Technol...

Data Science

150K€ Cerrado

TEJAM

Medical Technol...

Data Science

174K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2021-04-30
Fecha Fin: 2025-04-29

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bacteria which are resistant to antibiotics currently result in 33,000 deaths per annum in Europe alone. Antimicrobial Resistance (AMR) will potentially cost the EU an estimated €1.5 billion annually in healthcare expenses and productivity losses. By 2050, 10 million people are expected to die each year as a result of AMR-related infections. New strategies are urgently required to deal with this growing crisis. One such strategy involves the disruption of native bacterial communication systems, also known as quorum sensing. Bacteria typically communicate with one another using a ‘language’ based on small messenger molecules. In this way, a colony of bacteria can co-ordinate their responses to environmental stresses, such as the administration of an antibiotic. These responses come under a variety of forms, but one of the most common is the production of biofilm, which shields the bacteria from the effects of the antibiotic. The aim of this COUNTERMAND project is analyse the messenger molecules utilised by bacteria which controls their resistance mechanisms. We will create new molecules which serve to confuse the bacteria, and prevent them from launching their resistance countermeasures. By blocking the formation of biofilms, the bacteria will again be vulnerable to the effects of antibiotics. We will adopt a multidisciplinary and collaborative approach combining the talents of chemists in Ireland and microbiologists across the EU to find the most effective inhibitor molecules. Importantly, this approach means that a new lease of life can be given to current antibiotics, without the expense and risk involved in the discovery of new antibiotics. This COUNTERMAND project represents a novel and promising solution to tackling AMR, offering significantly improved quality of life for patients and increased life expectancies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores